Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...
Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) rose 10% Wednesday after the company reported positive six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular ...
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback